As MM cell lines are known to harbor more mutations in the NFκB pathway and are able to rapidly proliferate without the presence of a BM microenvironment, these studies further underline the importance of primary patient samples to study potential effects of NFκB-induced BFL-1 expression in MM. This evidence concerns the gene NFKB1 and Miyoshi myopathy.